Page 2 - John Koconis News Today

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology - read this article along with other careers information, tips and advice on BioSpace

Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001 BASKING...

Timber Pharmaceuticals has enrolled its first four patients in the phase 3 trial of its topical isotretinoin formula for the treatment of congenital ichthyosis, the company announced in a press release.TMB-001 0.05% is formulated using Timber’s patented IPEG delivery system and was granted an orphan drug designation by the FDA.

Press release content from NewMediaWire. The AP news staff was not involved in its creation.

Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022  BASKING RIDGE, NJ, May 12, 2022 (GLOBE...

Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting - read this article along with other careers information, tips and advice on BioSpace

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001 Timber PharmaceuticalsApril 28, 2021 GMT - Company is evaluating a topical pharmaceutical composition of isotretinoin for the treatment of moderate to severe subtypes of congenital ichthyosis - Basking Ridge, NJ, April 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire  -- Timber Pharmaceuticals, Inc. (“Timber” or...

Press release content from NewMediaWire. The AP news staff was not involved in its creation. Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001 Timber PharmaceuticalsDecember 15, 2020 GMT - Formal notice confirms intent to grant patent for pharmaceutical isotretinoin composition - WOODCLIFF LAKE, NJ - ( NewMediaWire ) - December 15, 2020 - Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a bioph...